Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Artivion

Artivion Shows Rising Relative Strength; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Artivion shows improving technical performance. Will it continue?

Investors Business Daily

Top US heart surgery device maker hit by ransomware attack

Artivion confirms security breach in new 8-K filing, saying the investigation is ongoing.

TechRadar

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap: Artivion Q4 Earnings

Artivion (NYSE:AORT) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Artivion missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.06.

Organisations

Investor Business Daily

820 stories

GSK

347 stories

Food and Drug Administration

European Medicines Agency

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Europe

27,980 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.